QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文 JOURNAL OF HEPATOLOGY, 2019, 卷号: 70 作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun 收藏  |  浏览/下载：56/0  |  提交时间：2019/12/05 Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV 期刊论文 BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 卷号: 124, 期号: 4 作者:  Niu, Wan-jie;  Sun, Tao;  Liu, Li;  Liu, Xiao-qian;  Zhang, Ren-fang 收藏  |  浏览/下载：24/0  |  提交时间：2019/12/05 Chinese patients  HIV  lopinavir  population pharmacokinetics  ritonavir  simulation   All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05 All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文 作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang 收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05